Wedbush Forecasts Higher Earnings for Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc (NASDAQ:FENC) – Stock analysts at Wedbush lifted their Q2 2025 earnings per share estimates for shares of Fennec Pharmaceuticals in a research report issued to clients and investors on Tuesday, May 13th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($0.05) per share for the quarter, up from their previous estimate of ($0.10). Wedbush has a “Outperform” rating and a $13.00 price objective on the stock. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is ($0.11) per share. Wedbush also issued estimates for Fennec Pharmaceuticals’ Q3 2025 earnings at $0.40 EPS, Q4 2025 earnings at $0.11 EPS, FY2025 earnings at $0.42 EPS, FY2026 earnings at $1.05 EPS and FY2027 earnings at $1.84 EPS.

Fennec Pharmaceuticals (NASDAQ:FENC) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.08. The firm had revenue of $8.51 million during the quarter, compared to the consensus estimate of $8.18 million. Fennec Pharmaceuticals had a negative return on equity of 53.38% and a negative net margin of 2.30%. During the same quarter in the previous year, the company posted $0.41 EPS.

A number of other research firms also recently weighed in on FENC. Craig Hallum boosted their target price on Fennec Pharmaceuticals from $12.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday. HC Wainwright restated a “buy” rating and set a $13.00 target price on shares of Fennec Pharmaceuticals in a research report on Tuesday, March 11th.

Fennec Pharmaceuticals Stock Up 4.4%

FENC stock opened at $6.84 on Friday. The company has a market cap of $188.74 million, a P/E ratio of -68.39 and a beta of 0.32. Fennec Pharmaceuticals has a twelve month low of $3.96 and a twelve month high of $7.64. The business has a fifty day moving average of $5.91 and a 200-day moving average of $5.93.

Insider Activity at Fennec Pharmaceuticals

In related news, Director Rosty Raykov sold 10,000 shares of the company’s stock in a transaction dated Friday, April 4th. The stock was sold at an average price of $5.25, for a total value of $52,500.00. Following the completion of the sale, the director now owns 61,156 shares in the company, valued at approximately $321,069. This represents a 14.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last quarter, insiders sold 30,000 shares of company stock worth $183,500. 11.76% of the stock is owned by insiders.

Institutional Investors Weigh In On Fennec Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in FENC. AQR Capital Management LLC acquired a new position in Fennec Pharmaceuticals in the first quarter valued at about $66,000. Nuveen LLC acquired a new position in shares of Fennec Pharmaceuticals during the first quarter worth about $158,000. AIGH Capital Management LLC acquired a new position in shares of Fennec Pharmaceuticals during the first quarter worth about $2,199,000. Pinnacle Wealth Planning Services Inc. acquired a new position in shares of Fennec Pharmaceuticals during the fourth quarter worth about $97,000. Finally, Bank of America Corp DE boosted its position in shares of Fennec Pharmaceuticals by 32.1% during the fourth quarter. Bank of America Corp DE now owns 35,827 shares of the company’s stock worth $226,000 after buying an additional 8,703 shares during the period. Institutional investors own 55.51% of the company’s stock.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.